Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

ClinicalTrials.gov ID: NCT02503345

Public ClinicalTrials.gov record NCT02503345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.

Study identification

NCT ID: NCT02503345
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Allena Pharmaceuticals; Industry
Enrollment: 32 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2015 (Type not available)
Primary completion: Aug 2016 (Actual)
Completion: Jan 2017 (Actual)
Last update posted: Jan 11, 2018

2015 – 2017

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Tower Urology	Los Angeles	California	90048	—
Atlantic Urological Associates	Daytona Beach	Florida	32114	—
Mayo Clinic - Nephrology And Hypertension	Jacksonville	Florida	32224	—
Northwestern Feinberg School Of Medicine - Urology Department	Chicago	Illinois	60611	—
IU Health Physicians Urology	Indianapolis	Indiana	46202	—
Anne Arundel Urology	Annapolis	Maryland	21401	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Mayo Clinic	Rochester	Minnesota	55902	—
Brooklyn Urology Research Group	Brooklyn	New York	11694	—
North Shore Long Island Jewish Health System/The Arthur Miller Institute for Urology	Lake Success	New York	11042	—
New York University - Division Of Nephrology	New York	New York	10016	—
The Urology Group	Cincinnati	Ohio	45212	—
Cleveland Clinic-Urology	Cleveland	Ohio	44195	—
Omega Clinical Research	Warwick	Rhode Island	02886	—
UT Southwestern Medical Center - Urology	Dallas	Texas	75390	—
Urology of Virginia	Virginia Beach	Virginia	23462	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02503345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 11, 2018 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02503345 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →